CA3216894A1 - An anti-tslp fab with improved stability - Google Patents

An anti-tslp fab with improved stability Download PDF

Info

Publication number
CA3216894A1
CA3216894A1 CA3216894A CA3216894A CA3216894A1 CA 3216894 A1 CA3216894 A1 CA 3216894A1 CA 3216894 A CA3216894 A CA 3216894A CA 3216894 A CA3216894 A CA 3216894A CA 3216894 A1 CA3216894 A1 CA 3216894A1
Authority
CA
Canada
Prior art keywords
fab
tslp
cells
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3216894A
Other languages
English (en)
French (fr)
Inventor
Roland Wilhelm Kolbeck
Emma Suzanne Cohen
Catherine Eugenie HUNTINGTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of CA3216894A1 publication Critical patent/CA3216894A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3216894A 2021-04-19 2022-04-19 An anti-tslp fab with improved stability Pending CA3216894A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21169183 2021-04-19
EP21169183.7 2021-04-19
PCT/EP2022/060236 WO2022223514A1 (en) 2021-04-19 2022-04-19 An anti-tslp fab with improved stability

Publications (1)

Publication Number Publication Date
CA3216894A1 true CA3216894A1 (en) 2022-10-27

Family

ID=75588042

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3216894A Pending CA3216894A1 (en) 2021-04-19 2022-04-19 An anti-tslp fab with improved stability

Country Status (19)

Country Link
US (1) US20240199730A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326767A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024516962A (cg-RX-API-DMAC7.html)
KR (1) KR20230172508A (cg-RX-API-DMAC7.html)
CN (1) CN117222665A (cg-RX-API-DMAC7.html)
AR (1) AR125379A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022263281A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021587A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216894A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003082A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015286A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230533A (cg-RX-API-DMAC7.html)
EC (1) ECSP23086870A (cg-RX-API-DMAC7.html)
IL (1) IL307651A (cg-RX-API-DMAC7.html)
MX (1) MX2023012266A (cg-RX-API-DMAC7.html)
PH (1) PH12023552762A1 (cg-RX-API-DMAC7.html)
SA (1) SA523451188B1 (cg-RX-API-DMAC7.html)
TW (1) TW202306982A (cg-RX-API-DMAC7.html)
WO (1) WO2022223514A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA129038C2 (uk) * 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
AR135161A1 (es) 2024-01-29 2026-07-08 Astrazeneca Ab Composiciones de fragmentos de unión a la linfopoyetina estromal tímica (tslp) y métodos de uso de las mismas
USD1126392S1 (en) 2024-05-16 2026-05-12 Astrazeneca Ab Inhaler
US20260034317A1 (en) 2024-05-20 2026-02-05 Medimmune Limited Inhaler and capsule for delivering thymic stromal lymphopoietin (tslp)-binding antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1306272C (zh) 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EP3609917A1 (en) * 2017-04-12 2020-02-19 Amgen Inc. Treatment of asthma with anti-tslp antibody
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合tslp及びその使用
UA129038C2 (uk) * 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)

Also Published As

Publication number Publication date
MX2023012266A (es) 2023-10-24
EP4326767A1 (en) 2024-02-28
IL307651A (en) 2023-12-01
KR20230172508A (ko) 2023-12-22
CL2023003082A1 (es) 2024-04-19
BR112023021587A2 (pt) 2023-12-19
AR125379A1 (es) 2023-07-12
US20240199730A1 (en) 2024-06-20
CO2023015286A2 (es) 2024-02-05
CN117222665A (zh) 2023-12-12
SA523451188B1 (ar) 2025-06-22
WO2022223514A1 (en) 2022-10-27
AU2022263281A1 (en) 2023-11-09
TW202306982A (zh) 2023-02-16
PH12023552762A1 (en) 2024-04-15
AU2022263281A9 (en) 2023-11-16
CR20230533A (es) 2024-04-05
ECSP23086870A (es) 2023-12-29
JP2024516962A (ja) 2024-04-18

Similar Documents

Publication Publication Date Title
US20240199730A1 (en) An anti-tslp fab with improved stability
KR102330596B1 (ko) 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CN105026428B (zh) PD‑l抗体、其抗原结合片段及其医药用途
CN101970489B (zh) 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
US11673950B2 (en) ILT7 binding molecules and methods of using the same
CN110540590B (zh) 一种自免疫抑制物的开发和应用
CN103974975B (zh) 抗假单胞菌Psl结合分子及其用途
KR101824512B1 (ko) 과립구-대식세포 콜로니 자극 인자에 대한 항체
CN112654640B (zh) 抗IL-1β的抗体、其药物组合物及其用途
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
CN114907479B (zh) 抗cd112r抗体及其用途
KR20230125042A (ko) 항-tslp 나노항체 및 이의 응용
US20200385453A1 (en) Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
WO2023036127A1 (zh) 一种靶向IL-23p19的抗体或其抗原结合片段及其应用
KR20240017006A (ko) 조작된 이중 결합 항체 및 이의 용도
TWI863317B (zh) 抗cd40抗體和抗pd-l1×cd40雙特異抗體及其應用
EA052142B1 (ru) Fab К TSLP С ПОВЫШЕННОЙ СТАБИЛЬНОСТЬЮ
CN117616043A (zh) 经工程化的双重结合抗体及其用途
JP5476310B2 (ja) hGM−CSFに結合するモノクローナル抗体および前記抗体を含む医薬組成物
WO2025108343A1 (zh) 靶向il-11的抗原结合蛋白
CN121135878A (zh) 针对ox40l和il-13的双特异性抗体及其用途
CN115340604A (zh) Tim-3全人源单克隆抗体及其应用
BR112018067951B1 (pt) Anticorpo anti- transcrito 7 semelhante à imunoglobulina, composição farmacêutica e uso dos mesmos
NZ721624B2 (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250402